This PDSB stock forecast article was written by Nicole Shammay – Analyst at I Know First.
Read The Full Premium Article “One of the biggest challenges to medicine is the incorporation of information technology in our practices.”
– Samuel Wilson
(Source: Air Force Medical Service)
Endo International plc, incorporated on October 31, 2013, is a generics and specialty branded pharmaceutical company. The company has three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals and International Pharmaceuticals. It has its own brand names and its non-branded U.S. Generic Pharmaceuticals portfolio consists of products, such as tablets, capsules, powders, injectables, liquids, nasal sprays, ophthalmics and patches. The International Pharmaceuticals segment includes various specialty pharmaceutical products for the Canadian, Latin American and world markets.
On June 26, I Know First gave a bullish one month forecast for ENDP. Over that one month period, the stock returned up to 30.67%. Navigating the drug industry, there are some key reasons why Endo stocks grew faster than its competitors:
Many analysts have been bearish on drug companies because of the decline in opioid sales. Accidental deaths and drug overdoses caused by opioids have spiked over the years and federal agencies are bringing major litigations to these drug companies. In the first half of 2018, Endo stock prices dipped to a low of $5.43 after being issued grand jury subpoenas. Apart from Endo, drug companies Mallinckrodt (MNK) and Insys (INSY) have seen their revenue and earnings fall due to government clamp on opioid prescriptions.
However, on July 20th, Endo and Mallinckrodt launched a counterattack against drug dealers, illegal websites, “dark web” retailers and corrupted healthcare providers. While some lawyers believe that drug companies would not be absolved from liability for the conduct of third parties, public confidence in Endo soared and reflected in the stock prices. The stock spiked 9.09% from July 20th to July 26th.
Opioids (Source: Flickr)
The counterattack seeks to shift any liabilities from Endo to individuals and companies who unlawfully sold prescription opioids, and hold them financially responsible for damages assessed against Endo. Charged individuals and entities include online retailer RxCash.Biz, which sells misbranded opioids, an Italian man indicted for of operating so-called pill mills, and a Tennessee resident who’s serving 10 years for possessing fentanyl with an intent to distribute. Furthermore, the US Food and Drug Administration is cracking down on websites like “AnonShop,” “Remedy Mart,” “TramadolHub” and “One Stop Pharma” that are illegally selling opioids.
Another spike came after July 2, when one of ENDO’s operating companies, Par Pharmaceutical, Inc. (Par), began shipping an authorized generic version of Takeda Pharmaceutical’s Colcrys® (colchicine, USP) 0.6 mg tablets. This tablet is indicated for prophylaxis and treatment of gout flares in adults and familial Mediterranean fever (FMF) in adults and children 4 years or older.
Endo also announced on July 25th that its subsidiary, Endo Ventures Limited has entered into definitive agreements with Bioprojet SCR to register, commercialize, and distribute pitolisant on an exclusive basis in Canada. Endo’s operating company, Paladin Labs Inc., will be commercializing pitolisant in Canada while Bioprojet will be responsible for supplying the drug to Paladin. The new revenue line continues to bring more revenue to Endo.
On June 26th, I Know First AI Algorithm gave a bullish 1 month forecast on Endo International plc (NASDAQ: ENDP). The Forecast shows a signal of 5.18 and a predictability of 0.36. In agreement with the forecast, ENDP has returned 30.67% over the one month period, demonstrating the accuracy of the I Know First Algorithm.
This is the second month ENDP stocks has successfully risen since our June forecast. Read the June analysis here.
How to read the I Know First Forecast and Heatmap
Please note-for trading decisions use the most recent forecast.
Get today’s forecast and Top stock picks.
This article was written by Julia Masch, a Financial Analyst at I Know First.
Highlights
Read The Full Premium ArticleSubscribe to receive exclusive PREMIUM content here
– Barry D. Quart, Pharm.D., CEO of Heron Therapeutics.
(Source: smarteranalyst.com)
Just in three months from March 25th, 2018, Heron Therapeutics Inc (NYSE: HRTX) has gained 46.99%. The main reason for such an incredible movement is the news released on June 25th that HTX-011 has received the Breakthrough Therapy designation from the FDA. HTX-011 is an investigational, and long-acting formulation for Postoperative Pain Management, developed by HRTX.
The formulation achieved the designation thanks to the Phase 2 and some of Phase 3 studies. The Breakthrough Therapy designation allows Heron Therapeutics to expedite the development of the drugs. The success of HTX-011 will significantly reduce the postoperative pain intensity as well as the addiction of opioids. Opioids are a class of drugs that are used as medicines to relieve pain and relax the body. According to Heron Therapeutics, there are more than 40 million patients who undergoing surgical procedures are prescribed to this class of drugs. Out of 40 million, 2.6 become persistent users, while 440,000 become addicted. Hence, if success, HTX-011 will become a huge solution for postoperative pain management.
(Source: Centers for Disease Control and Prevention)
On May 25, 2017, I Know First has issued a bullish 3-month prediction for HRTX with the signal of 28.44 and the predictability of 0.53. 3 months after the bullish signal, HRTX shot up to $41.45 (46.99% upside), in line with our forecast.
Current I Know First subscribers received this bullish XOMA forecast on March 25, 2018.
To subscribe today click here.
How to interpret this diagram
Please note-for trading decisions use the most recent forecast. Get today’s forecast and Top stock picks.
Heron Therapeutics, Inc., (NASDAQ: HRTX) incorporated on February 5, 1987, is a biotechnology company. The Company is engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology (Biochronomer technology), which can deliver therapeutic levels of a range of otherwise short-acting pharmacological agents over a period of days to weeks with a single subcutaneous injection. The Company’s product candidate, SUSTOL (granisetron) injection, extended release, is being developed for the prevention of both acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC). SUSTOL is in Phase III clinical trials. The New Drug Application (NDA) is under review by the United States Food and Drug Administration (FDA) for SUSTOL. The Company has initiated a placebo-controlled, dose-finding, Phase II clinical trial for HTX-011 in approximately 100 patients undergoing abdominoplasty. HTX-011 is also being evaluated in a placebo-controlled, dose-finding, Phase II clinical trial in approximately 100 patients undergoing inguinal hernia repair.
Before making any trading decisions, consult the latest forecast as the algorithm updates predictions daily. You can use the algorithm for intra-day trading. The predictability tends to become stronger with forecasts over longer time-horizons such as the 1-month, 3-month and 1-year forecasts.
Disclaimer:
I Know First-Daily Market Forecast, does not provide personal investment or financial advice to individuals, or act as personal financial, legal, or institutional investment advisors, or individually advocate the purchase or sale of any security or investment or the use of any particular financial strategy. All investing, stock forecasts and investment strategies include the risk of loss for some or even all of your capital. Before pursuing any financial strategies discussed on this website, you should always consult with a licensed financial advisor.
